---
document_datetime: 2025-11-23 13:10:50
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/helixate-nexgen.html
document_name: helixate-nexgen.html
version: success
processing_time: 0.1183913
conversion_datetime: 2025-12-26 13:02:37.854068
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Helixate NexGen

[RSS](/en/individual-human-medicine.xml/66153)

##### Withdrawn

This medicine's authorisation has been withdrawn

octocog alfa

Medicine

Human

Withdrawn

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Helixate NexGen](#news-on)
- [More information on Helixate NexGen](#more-information-on-helixate-nexgen-633)
- [More information on Helixate NexGen](#related-medicines)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

On 16 December 2019, the European Commission withdrew the marketing authorisation for Helixate NexGen (SRD) (octocog alfa) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Bayer AG, which notified the European Commission of its decision not to market the product in the EU for commercial reasons.

Helixate NexGen (SRD) was granted marketing authorisation in the EU on 4 August 2000 for treatment of haemophilia A. The marketing authorisation was initially valid for a 5-year period. It was subsequently renewed for an additional 5-year period in 2010. It was then granted unlimited validity in 2010. The product had not been marketed in the EU since 2019. Helixate NexGen (SRD) is an identical product to Kogenate Bayer. The marketing authorisation holder will maintain the marketing authorisation for Kogenate Bayer.

The European Public Assessment Report (EPAR) for Helixate NexGen (SRD) is updated to indicate that the marketing authorisation is no longer valid.

Helixate NexGen : EPAR - Summary for the public

English (EN) (674.79 KB - PDF)

**First published:** 12/05/2009

**Last updated:** 02/06/2020

[View](/en/documents/overview/helixate-nexgen-epar-summary-public_en.pdf)

[Other languages (21)](#file-language-dropdown-93)

български (BG) (768.2 KB - PDF)

**First published:**

12/05/2009

**Last updated:**

02/06/2020

[View](/bg/documents/overview/helixate-nexgen-epar-summary-public_bg.pdf)

español (ES) (672.9 KB - PDF)

**First published:**

12/05/2009

**Last updated:**

02/06/2020

[View](/es/documents/overview/helixate-nexgen-epar-summary-public_es.pdf)

čeština (CS) (728.75 KB - PDF)

**First published:**

12/05/2009

**Last updated:**

02/06/2020

[View](/cs/documents/overview/helixate-nexgen-epar-summary-public_cs.pdf)

dansk (DA) (652.35 KB - PDF)

**First published:**

12/05/2009

**Last updated:**

02/06/2020

[View](/da/documents/overview/helixate-nexgen-epar-summary-public_da.pdf)

Deutsch (DE) (652.26 KB - PDF)

**First published:**

12/05/2009

**Last updated:**

02/06/2020

[View](/de/documents/overview/helixate-nexgen-epar-summary-public_de.pdf)

eesti keel (ET) (670.26 KB - PDF)

**First published:**

12/05/2009

**Last updated:**

02/06/2020

[View](/et/documents/overview/helixate-nexgen-epar-summary-public_et.pdf)

ελληνικά (EL) (773.88 KB - PDF)

**First published:**

12/05/2009

**Last updated:**

02/06/2020

[View](/el/documents/overview/helixate-nexgen-epar-summary-public_el.pdf)

français (FR) (652.41 KB - PDF)

**First published:**

12/05/2009

**Last updated:**

02/06/2020

[View](/fr/documents/overview/helixate-nexgen-epar-summary-public_fr.pdf)

italiano (IT) (671.13 KB - PDF)

**First published:**

12/05/2009

**Last updated:**

02/06/2020

[View](/it/documents/overview/helixate-nexgen-epar-summary-public_it.pdf)

latviešu valoda (LV) (735.33 KB - PDF)

**First published:**

12/05/2009

**Last updated:**

02/06/2020

[View](/lv/documents/overview/helixate-nexgen-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (701.69 KB - PDF)

**First published:**

12/05/2009

**Last updated:**

02/06/2020

[View](/lt/documents/overview/helixate-nexgen-epar-summary-public_lt.pdf)

magyar (HU) (744.98 KB - PDF)

**First published:**

12/05/2009

**Last updated:**

02/06/2020

[View](/hu/documents/overview/helixate-nexgen-epar-summary-public_hu.pdf)

Malti (MT) (772.61 KB - PDF)

**First published:**

12/05/2009

**Last updated:**

02/06/2020

[View](/mt/documents/overview/helixate-nexgen-epar-summary-public_mt.pdf)

Nederlands (NL) (672.62 KB - PDF)

**First published:**

12/05/2009

**Last updated:**

02/06/2020

[View](/nl/documents/overview/helixate-nexgen-epar-summary-public_nl.pdf)

polski (PL) (729.14 KB - PDF)

**First published:**

12/05/2009

**Last updated:**

02/06/2020

[View](/pl/documents/overview/helixate-nexgen-epar-summary-public_pl.pdf)

português (PT) (649.2 KB - PDF)

**First published:**

12/05/2009

**Last updated:**

02/06/2020

[View](/pt/documents/overview/helixate-nexgen-epar-summary-public_pt.pdf)

română (RO) (701.16 KB - PDF)

**First published:**

12/05/2009

**Last updated:**

02/06/2020

[View](/ro/documents/overview/helixate-nexgen-epar-summary-public_ro.pdf)

slovenčina (SK) (751.06 KB - PDF)

**First published:**

12/05/2009

**Last updated:**

02/06/2020

[View](/sk/documents/overview/helixate-nexgen-epar-summary-public_sk.pdf)

slovenščina (SL) (741.26 KB - PDF)

**First published:**

12/05/2009

**Last updated:**

02/06/2020

[View](/sl/documents/overview/helixate-nexgen-epar-summary-public_sl.pdf)

Suomi (FI) (670.86 KB - PDF)

**First published:**

12/05/2009

**Last updated:**

02/06/2020

[View](/fi/documents/overview/helixate-nexgen-epar-summary-public_fi.pdf)

svenska (SV) (673.15 KB - PDF)

**First published:**

12/05/2009

**Last updated:**

02/06/2020

[View](/sv/documents/overview/helixate-nexgen-epar-summary-public_sv.pdf)

## Product information

Helixate NexGen : EPAR - Product information

English (EN) (934.15 KB - PDF)

**First published:** 12/11/2009

**Last updated:** 02/06/2020

[View](/en/documents/product-information/helixate-nexgen-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-518)

български (BG) (2.17 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

02/06/2020

[View](/bg/documents/product-information/helixate-nexgen-epar-product-information_bg.pdf)

español (ES) (1.17 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

02/06/2020

[View](/es/documents/product-information/helixate-nexgen-epar-product-information_es.pdf)

čeština (CS) (1.86 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

02/06/2020

[View](/cs/documents/product-information/helixate-nexgen-epar-product-information_cs.pdf)

dansk (DA) (1.12 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

02/06/2020

[View](/da/documents/product-information/helixate-nexgen-epar-product-information_da.pdf)

Deutsch (DE) (1.17 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

02/06/2020

[View](/de/documents/product-information/helixate-nexgen-epar-product-information_de.pdf)

eesti keel (ET) (1.14 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

02/06/2020

[View](/et/documents/product-information/helixate-nexgen-epar-product-information_et.pdf)

ελληνικά (EL) (2.21 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

02/06/2020

[View](/el/documents/product-information/helixate-nexgen-epar-product-information_el.pdf)

français (FR) (1.21 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

02/06/2020

[View](/fr/documents/product-information/helixate-nexgen-epar-product-information_fr.pdf)

hrvatski (HR) (1.23 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

02/06/2020

[View](/hr/documents/product-information/helixate-nexgen-epar-product-information_hr.pdf)

íslenska (IS) (1.01 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

02/06/2020

[View](/is/documents/product-information/helixate-nexgen-epar-product-information_is.pdf)

italiano (IT) (1.18 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

02/06/2020

[View](/it/documents/product-information/helixate-nexgen-epar-product-information_it.pdf)

latviešu valoda (LV) (1.92 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

02/06/2020

[View](/lv/documents/product-information/helixate-nexgen-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.23 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

02/06/2020

[View](/lt/documents/product-information/helixate-nexgen-epar-product-information_lt.pdf)

magyar (HU) (1.57 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

02/06/2020

[View](/hu/documents/product-information/helixate-nexgen-epar-product-information_hu.pdf)

Malti (MT) (1.95 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

02/06/2020

[View](/mt/documents/product-information/helixate-nexgen-epar-product-information_mt.pdf)

Nederlands (NL) (1.19 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

02/06/2020

[View](/nl/documents/product-information/helixate-nexgen-epar-product-information_nl.pdf)

norsk (NO) (1 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

02/06/2020

[View](/no/documents/product-information/helixate-nexgen-epar-product-information_no.pdf)

polski (PL) (1.93 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

02/06/2020

[View](/pl/documents/product-information/helixate-nexgen-epar-product-information_pl.pdf)

português (PT) (1.16 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

02/06/2020

[View](/pt/documents/product-information/helixate-nexgen-epar-product-information_pt.pdf)

română (RO) (1.24 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

02/06/2020

[View](/ro/documents/product-information/helixate-nexgen-epar-product-information_ro.pdf)

slovenčina (SK) (1.88 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

02/06/2020

[View](/sk/documents/product-information/helixate-nexgen-epar-product-information_sk.pdf)

slovenščina (SL) (1.79 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

02/06/2020

[View](/sl/documents/product-information/helixate-nexgen-epar-product-information_sl.pdf)

Suomi (FI) (1.16 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

02/06/2020

[View](/fi/documents/product-information/helixate-nexgen-epar-product-information_fi.pdf)

svenska (SV) (1.18 MB - PDF)

**First published:**

12/11/2009

**Last updated:**

02/06/2020

[View](/sv/documents/product-information/helixate-nexgen-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** A31/0178 16/11/2017

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Helixate NexGen : EPAR - All authorised presentations

English (EN) (584.47 KB - PDF)

**First published:** 21/01/2008

**Last updated:** 02/06/2020

[View](/en/documents/all-authorised-presentations/helixate-nexgen-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-960)

български (BG) (625.66 KB - PDF)

**First published:**

21/01/2008

**Last updated:**

02/06/2020

[View](/bg/documents/all-authorised-presentations/helixate-nexgen-epar-all-authorised-presentations_bg.pdf)

español (ES) (580.81 KB - PDF)

**First published:**

21/01/2008

**Last updated:**

02/06/2020

[View](/es/documents/all-authorised-presentations/helixate-nexgen-epar-all-authorised-presentations_es.pdf)

čeština (CS) (611.81 KB - PDF)

**First published:**

21/01/2008

**Last updated:**

02/06/2020

[View](/cs/documents/all-authorised-presentations/helixate-nexgen-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (580.7 KB - PDF)

**First published:**

21/01/2008

**Last updated:**

02/06/2020

[View](/da/documents/all-authorised-presentations/helixate-nexgen-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (580.46 KB - PDF)

**First published:**

21/01/2008

**Last updated:**

02/06/2020

[View](/de/documents/all-authorised-presentations/helixate-nexgen-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (580.66 KB - PDF)

**First published:**

21/01/2008

**Last updated:**

02/06/2020

[View](/et/documents/all-authorised-presentations/helixate-nexgen-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (631.23 KB - PDF)

**First published:**

21/01/2008

**Last updated:**

02/06/2020

[View](/el/documents/all-authorised-presentations/helixate-nexgen-epar-all-authorised-presentations_el.pdf)

français (FR) (580.57 KB - PDF)

**First published:**

21/01/2008

**Last updated:**

02/06/2020

[View](/fr/documents/all-authorised-presentations/helixate-nexgen-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (595.81 KB - PDF)

**First published:**

21/01/2008

**Last updated:**

02/06/2020

[View](/hr/documents/all-authorised-presentations/helixate-nexgen-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (580.52 KB - PDF)

**First published:**

21/01/2008

**Last updated:**

02/06/2020

[View](/is/documents/all-authorised-presentations/helixate-nexgen-epar-all-authorised-presentations_is.pdf)

italiano (IT) (580.46 KB - PDF)

**First published:**

21/01/2008

**Last updated:**

02/06/2020

[View](/it/documents/all-authorised-presentations/helixate-nexgen-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (614.96 KB - PDF)

**First published:**

21/01/2008

**Last updated:**

02/06/2020

[View](/lv/documents/all-authorised-presentations/helixate-nexgen-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (590.15 KB - PDF)

**First published:**

21/01/2008

**Last updated:**

02/06/2020

[View](/lt/documents/all-authorised-presentations/helixate-nexgen-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (610.4 KB - PDF)

**First published:**

21/01/2008

**Last updated:**

02/06/2020

[View](/hu/documents/all-authorised-presentations/helixate-nexgen-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (614.17 KB - PDF)

**First published:**

21/01/2008

**Last updated:**

02/06/2020

[View](/mt/documents/all-authorised-presentations/helixate-nexgen-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (585.56 KB - PDF)

**First published:**

21/01/2008

**Last updated:**

02/06/2020

[View](/nl/documents/all-authorised-presentations/helixate-nexgen-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (580.65 KB - PDF)

**First published:**

21/01/2008

**Last updated:**

02/06/2020

[View](/no/documents/all-authorised-presentations/helixate-nexgen-epar-all-authorised-presentations_no.pdf)

polski (PL) (612.89 KB - PDF)

**First published:**

21/01/2008

**Last updated:**

02/06/2020

[View](/pl/documents/all-authorised-presentations/helixate-nexgen-epar-all-authorised-presentations_pl.pdf)

português (PT) (581.98 KB - PDF)

**First published:**

21/01/2008

**Last updated:**

02/06/2020

[View](/pt/documents/all-authorised-presentations/helixate-nexgen-epar-all-authorised-presentations_pt.pdf)

română (RO) (596.88 KB - PDF)

**First published:**

21/01/2008

**Last updated:**

02/06/2020

[View](/ro/documents/all-authorised-presentations/helixate-nexgen-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (611.6 KB - PDF)

**First published:**

21/01/2008

**Last updated:**

02/06/2020

[View](/sk/documents/all-authorised-presentations/helixate-nexgen-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (596.06 KB - PDF)

**First published:**

21/01/2008

**Last updated:**

02/06/2020

[View](/sl/documents/all-authorised-presentations/helixate-nexgen-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (580.75 KB - PDF)

**First published:**

21/01/2008

**Last updated:**

02/06/2020

[View](/fi/documents/all-authorised-presentations/helixate-nexgen-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (584.26 KB - PDF)

**First published:**

21/01/2008

**Last updated:**

02/06/2020

[View](/sv/documents/all-authorised-presentations/helixate-nexgen-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Helixate NexGen Active substance octocog alfa International non-proprietary name (INN) or common name octocog alfa Therapeutic area (MeSH) Hemophilia A Anatomical therapeutic chemical (ATC) code B02BD02

### Pharmacotherapeutic group

Antihemorrhagics

### Therapeutic indication

Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor-VIII deficiency).

This preparation does not contain von Willebrand factor and is therefore not indicated in von Willebrand's disease.

## Authorisation details

EMA product number EMEA/H/C/000276 Marketing authorisation holder

Bayer AG

51368 Leverkusen Germany

Marketing authorisation issued 04/08/2000 Revision 31

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Helixate NexGen : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (986.42 KB - PDF)

**First published:** 12/11/2009

**Last updated:** 02/06/2020

[View](/en/documents/procedural-steps-after/helixate-nexgen-epar-procedural-steps-taken-and-scientific-information-after-authorisation_en.pdf)

Helixate NexGen-H-C-0276-A31-0178 : EPAR - Assessment Report - Article 31

Adopted

Reference Number: EMA/763977/2017

English (EN) (905.6 KB - PDF)

**First published:** 05/12/2017

**Last updated:** 02/06/2020

[View](/en/documents/variation-report/helixate-nexgen-h-c-0276-a31-0178-epar-assessment-report-article-31_en.pdf)

Helixate NexGen-H-C-A20-143 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

English (EN) (651.08 KB - PDF)

**First published:** 20/03/2014

**Last updated:** 02/06/2020

[View](/en/documents/scientific-conclusion/helixate-nexgen-h-c-a20-143-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

[Other languages (22)](#file-language-dropdown-847)

български (BG) (844.19 KB - PDF)

**First published:**

20/03/2014

**Last updated:**

02/06/2020

[View](/bg/documents/scientific-conclusion/helixate-nexgen-h-c-a20-143-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_bg.pdf)

español (ES) (658.41 KB - PDF)

**First published:**

20/03/2014

**Last updated:**

02/06/2020

[View](/es/documents/scientific-conclusion/helixate-nexgen-h-c-a20-143-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_es.pdf)

čeština (CS) (802.29 KB - PDF)

**First published:**

20/03/2014

**Last updated:**

02/06/2020

[View](/cs/documents/scientific-conclusion/helixate-nexgen-h-c-a20-143-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_cs.pdf)

dansk (DA) (655.05 KB - PDF)

**First published:**

20/03/2014

**Last updated:**

02/06/2020

[View](/da/documents/scientific-conclusion/helixate-nexgen-h-c-a20-143-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_da.pdf)

Deutsch (DE) (665.36 KB - PDF)

**First published:**

20/03/2014

**Last updated:**

02/06/2020

[View](/de/documents/scientific-conclusion/helixate-nexgen-h-c-a20-143-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_de.pdf)

eesti keel (ET) (654.65 KB - PDF)

**First published:**

20/03/2014

**Last updated:**

02/06/2020

[View](/et/documents/scientific-conclusion/helixate-nexgen-h-c-a20-143-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_et.pdf)

ελληνικά (EL) (867.86 KB - PDF)

**First published:**

20/03/2014

**Last updated:**

02/06/2020

[View](/el/documents/scientific-conclusion/helixate-nexgen-h-c-a20-143-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_el.pdf)

français (FR) (655.34 KB - PDF)

**First published:**

20/03/2014

**Last updated:**

02/06/2020

[View](/fr/documents/scientific-conclusion/helixate-nexgen-h-c-a20-143-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_fr.pdf)

hrvatski (HR) (699.51 KB - PDF)

**First published:**

20/03/2014

**Last updated:**

02/06/2020

[View](/hr/documents/scientific-conclusion/helixate-nexgen-h-c-a20-143-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_hr.pdf)

italiano (IT) (655.65 KB - PDF)

**First published:**

20/03/2014

**Last updated:**

02/06/2020

[View](/it/documents/scientific-conclusion/helixate-nexgen-h-c-a20-143-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_it.pdf)

latviešu valoda (LV) (811.59 KB - PDF)

**First published:**

20/03/2014

**Last updated:**

02/06/2020

[View](/lv/documents/scientific-conclusion/helixate-nexgen-h-c-a20-143-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_lv.pdf)

lietuvių kalba (LT) (699.72 KB - PDF)

**First published:**

20/03/2014

**Last updated:**

02/06/2020

[View](/lt/documents/scientific-conclusion/helixate-nexgen-h-c-a20-143-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_lt.pdf)

magyar (HU) (787.75 KB - PDF)

**First published:**

20/03/2014

**Last updated:**

02/06/2020

[View](/hu/documents/scientific-conclusion/helixate-nexgen-h-c-a20-143-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_hu.pdf)

Malti (MT) (789.62 KB - PDF)

**First published:**

20/03/2014

**Last updated:**

02/06/2020

[View](/mt/documents/scientific-conclusion/helixate-nexgen-h-c-a20-143-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_mt.pdf)

Nederlands (NL) (656.85 KB - PDF)

**First published:**

20/03/2014

**Last updated:**

02/06/2020

[View](/nl/documents/scientific-conclusion/helixate-nexgen-h-c-a20-143-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_nl.pdf)

polski (PL) (802.69 KB - PDF)

**First published:**

20/03/2014

**Last updated:**

02/06/2020

[View](/pl/documents/scientific-conclusion/helixate-nexgen-h-c-a20-143-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_pl.pdf)

português (PT) (663.08 KB - PDF)

**First published:**

20/03/2014

**Last updated:**

02/06/2020

[View](/pt/documents/scientific-conclusion/helixate-nexgen-h-c-a20-143-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_pt.pdf)

română (RO) (707.66 KB - PDF)

**First published:**

20/03/2014

**Last updated:**

02/06/2020

[View](/ro/documents/scientific-conclusion/helixate-nexgen-h-c-a20-143-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_ro.pdf)

slovenčina (SK) (824.85 KB - PDF)

**First published:**

20/03/2014

**Last updated:**

02/06/2020

[View](/sk/documents/scientific-conclusion/helixate-nexgen-h-c-a20-143-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_sk.pdf)

slovenščina (SL) (788.52 KB - PDF)

**First published:**

20/03/2014

**Last updated:**

02/06/2020

[View](/sl/documents/scientific-conclusion/helixate-nexgen-h-c-a20-143-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_sl.pdf)

Suomi (FI) (658.67 KB - PDF)

**First published:**

20/03/2014

**Last updated:**

02/06/2020

[View](/fi/documents/scientific-conclusion/helixate-nexgen-h-c-a20-143-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_fi.pdf)

svenska (SV) (663.08 KB - PDF)

**First published:**

20/03/2014

**Last updated:**

02/06/2020

[View](/sv/documents/scientific-conclusion/helixate-nexgen-h-c-a20-143-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_sv.pdf)

Helixate NexGen-H-C-276-A20-143 : EPAR - Assessment Report - Article 20

Adopted

Reference Number: EMA/10430/2014

English (EN) (798.1 KB - PDF)

**First published:** 20/03/2014

**Last updated:** 02/06/2020

[View](/en/documents/variation-report/helixate-nexgen-h-c-276-a20-143-epar-assessment-report-article-20_en.pdf)

Helixate NexGen-H-C-276-WS-193 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/282360/2012

English (EN) (1.3 MB - PDF)

**First published:** 21/05/2012

**Last updated:** 02/06/2020

[View](/en/documents/variation-report/helixate-nexgen-h-c-276-ws-193-epar-assessment-report-variation_en.pdf)

Helixate NexGen : EPAR - Steps taken after authorisation when a cutoff date has been used

English (EN) (660.51 KB - PDF)

**First published:** 06/11/2006

**Last updated:** 02/06/2020

[View](/en/documents/steps-after-cutoff/helixate-nexgen-epar-steps-taken-after-authorisation-when-cutoff-date-has-been-used_en.pdf)

## Initial marketing authorisation documents

Helixate NexGen : EPAR - Scientific Discussion

English (EN) (985.68 KB - PDF)

**First published:** 06/11/2006

**Last updated:** 02/06/2020

[View](/en/documents/scientific-discussion/helixate-nexgen-epar-scientific-discussion_en.pdf)

Helixate NexGen : EPAR - Procedural steps taken before authorisation

English (EN) (659.67 KB - PDF)

**First published:** 06/11/2006

**Last updated:** 02/06/2020

[View](/en/documents/procedural-steps/helixate-nexgen-epar-procedural-steps-taken-authorisation_en.pdf)

#### News on Helixate NexGen

[Factor VIII medicines: no clear and consistent evidence of difference in risk of inhibitor development between classes](/en/news/factor-viii-medicines-no-clear-consistent-evidence-difference-risk-inhibitor-development-between-classes) 15/09/2017

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 10-13 May 2016](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-10-13-may-2016) 13/05/2016

[CHMP confirms PRAC recommendations on Kogenate Bayer/Helixate NexGen](/en/news/chmp-confirms-prac-recommendations-kogenate-bayer-helixate-nexgen) 20/12/2013

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 16-19 December 2013](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-16-19-december-2013) 20/12/2013

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 2-5 December 2013](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-2-5-december-2013) 06/12/2013

[PRAC considers benefits of Kogenate Bayer/Helixate NexGen outweigh risks in previously untreated patients](/en/news/prac-considers-benefits-kogenate-bayer-helixate-nexgen-outweigh-risks-previously-untreated-patients) 06/12/2013

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 4-7 March 2013](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-4-7-march-2013) 08/03/2013

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 12-15 March 2012](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-12-15-march-2012) 16/03/2012

#### More information on Helixate NexGen

- [Kogenate Bayer and Helixate NexGen](/en/medicines/human/referrals/kogenate-bayer-helixate-nexgen)

Questions and answers on the outcome of extension of indication application for Kogenate Bayer and Helixate Nexgen (octocog alfa)

English (EN) (610.22 KB - PDF)

**First published:** 22/03/2012

**Last updated:** 22/03/2012

[View](/en/documents/medicine-qa/questions-and-answers-outcome-extension-indication-application-kogenate-bayer-and-helixate-nexgen-octocog-alfa_en.pdf)

#### More information on Helixate NexGen

- [Factor VIII - referral](/en/medicines/human/referrals/factor-viii)

**This page was last updated on** 02/06/2020

## Share this page

[Back to top](#main-content)